Leukotriene antagonists and symptom control in chronic persistent asthma

This publication has 18 references indexed in Scilit:

• Zafirlukast Improves Asthma Control in Patients Receiving High-Dose Inhaled Corticosteroids
  American Journal of Respiratory and Critical Care Medicine, 2000
• Induced Sputum Eicosanoid Concentrations in Asthma
  American Journal of Respiratory and Critical Care Medicine, 1999
• Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial
  European Respiratory Journal, 1999
• The effect of montelukast (MK‐0476), a cysteinyl leukotriene receptor antagonist, on allergen‐induced airway responses and sputum cell counts in asthma
  Clinical and Experimental Allergy, 1999
• Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction
  New England Journal of Medicine, 1998
• Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids
  Thorax, 1997
• Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group.
  American Journal of Respiratory and Critical Care Medicine, 1994
• Role of Leukotrienes in Exercise-induced Asthma: Inhibitory Effect of ICI 204219, a Potent Leukotriene D₄Receptor Antagonist
  American Review of Respiratory Disease, 1992
• Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects
  The Lancet, 1991
• Inhibition of Exercise-Induced Bronchoconstriction by MK-571, a Potent Leukotriene D₄–Receptor Antagonist
  New England Journal of Medicine, 1990